Navigation Links
Cancer stem cells recruit normal stem cells to fuel ovarian cancer, U-M study finds

ANN ARBOR, Mich. Researchers at the University of Michigan Comprehensive Cancer Center have found that a type of normal stem cell fuels ovarian cancer by encouraging cancer stem cells to grow.

Cancer stem cells are the small number of cells in a tumor that drive its growth and spread. Traditional cancer treatments do not kill these cells, which is why cancer treatments often fail.

In a study published online in the Journal of Clinical Investigation, researchers looked in ovarian tissue at the mesenchymal stem cells, which are normal cells found throughout the body. These cells can form different specialized cells such as fat, bone or cartilage.

Mesenchymal stem cells are known to be helpful with wound healing, which has many scientists conjecturing that they may help combat cancer. In this study, the researchers observed that mesenchymal stem cells in ovarian tumors were different than mesenchymal stem cells from healthy ovaries. And in fact, the mesenchymal stem cells in the ovarian tumors were fueling the cancer.

"Cancer is very good at tricking the mesenchymal stem cells into doing what the cancer likes. The cancer takes the cells hostage and uses them to promote the cancer's growth," says study author Ronald Buckanovich, M.D., Ph.D., assistant professor of internal medicine and of obstetrics and gynecology at the U-M Medical School.

The researchers used mouse models and human tissue samples of both normal ovaries and ovarian cancer, to look at what happened to the mesenchymal stem cells. They also noticed the cancer-associated mesenchymal stem cells increased tumor size, primarily by increasing the number of cancer stem cells.

At the same time, the researchers saw that a type of protein called BMP2 was prevalent in the cancer-associated mesenchymal stem cells. BMP2 is a so-called master regulatory protein, and is carefully regulated in normal cell function. The researchers found more than three times the amount of BMP in the cancer-associated mesenchymal stem cells than in the normal ones. When BMP was added to cancer cells, it led to an increase in cancer stem cells.

The researchers then used a known BMP inhibitor called Noggin, and found that Noggin blocked the mesenchymal stem cells from triggering this cancer stem cell growth.

"High doses of Noggin might not be tolerated in humans," Buckanovich says. "Our next step is to figure out how to target Noggin directly to the vascular niche where the mesenchymal stem cells and cancer stem cells live. This would allow us to make it safer to use Noggin as a potential treatment for ovarian cancer."

This research must continue in the laboratory before it can be advanced to clinical trials in patients. In the meantime, the U-M Comprehensive Cancer Center expects to open two new clinical trials within the next year testing other therapies aimed at attacking ovarian cancer stem cells. For information, contact the Cancer AnswerLine at 800-865-1125.

Ovarian cancer statistics: 21,880 Americans will be diagnosed with ovarian cancer this year and 13,850 will die from the disease, according to the American Cancer Society


Contact: Nicole Fawcett
University of Michigan Health System

Related biology news :

1. Trastuzumab and chemotherapy improved survival in HER2-postive breast and brain cancer patients
2. UT Southwestern research reveals that significantly more genetic mutations lead to colon cancer
3. Cancer gene therapy from camels
4. Cancer data not readily available for future research
5. UT faculty improving surgical outcomes for children, cancer patients
6. Study explains why men are at higher risk for stomach cancer
7. Stem cells restore cognitive abilities impaired by brain cancer treatment
8. PSA test for men could get a second life for breast cancer in women
9. Low dose naltrexone (LDN): Harnessing the bodys own chemistry to treat human ovarian cancer
10. GNS Healthcare Collaborates with NCI in New Approach to Lung Cancer; Supercomputer Analysis to Aid in Matching Targeted Drugs to Patients
11. AACR hosts Frontiers in Basic Cancer Research Conference in San Francisco
Post Your Comments:
Related Image:
Cancer stem cells recruit normal stem cells to fuel ovarian cancer, U-M study finds 
(Date:6/27/2016)... Research and Markets has announced the addition ... to their offering. The report ... to grow at a CAGR of 12.28% during the period 2016-2020. ... in-depth market analysis with inputs from industry experts. The report covers ... The report also includes a discussion of the key vendors operating ...
(Date:6/22/2016)...  The American College of Medical Genetics and Genomics was ... as one of the fastest-growing trade shows during the Fastest ... in Las Vegas . ... in each of the following categories: net square feet of ... attendees. The 2015 ACMG Annual Meeting was ranked 23 out ...
(Date:6/22/2016)... LOS ANGELES , June 22, 2016 ... of identity management and verification solutions, has ... cutting edge software solutions for Visitor Management, ... ® provides products that add functional ... The partnership provides corporations and venues with ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Alex,s Lemonade ... announced that that it will open a state-of-the-art bioinformatics ... childhood cancer research. This announcement comes as Liz ... attends the National Cancer Moonshot Summit in ... Dr. Biden as a participant and advocate of pediatric ...
(Date:6/27/2016)...  Global demand for enzymes is forecast to ... $7.2 billion.  This market includes enzymes used in ... production, animal feed, and other markets) and specialty ... and beverages will remain the largest market for ... products containing enzymes in developing regions.  These and ...
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... -- Sequenom, Inc. (NASDAQ: SQNM ), a life ... development of innovative products and services, announced today that ... denied its petition to review decisions by ... Patent No. 6,258,540 (",540 Patent") are not patent eligible ... Court,s Mayo Collaborative Services v. Prometheus Laboratories decision.  In ...
Breaking Biology Technology: